As KaloCyte has re-established itself in Maryland, Elaine E. Haynes, President and CEO, said they are moving closer to bringing their artificial blood cell product, ErythroMer, to clinical trials and are eyeing a Series A funding round later this year.
Maryland Booms in the BioCapital Hotbed
